Longterm safety and efficacy of adalimumab and infliximab for uveitis associated with juvenile idiopathic arthritis
| Autor: | Irene Pontikaki, Claudia Bracaglia, Riccardo De Marco, Silvana Martino, Giorgia Martini, Antonella Petaccia, Francesco Zulian, Elisabetta Miserocchi, Francesco La Torre, Fabio Vittadello, Maria Pia Paroli, Gabriele Simonini, Francesco Comacchio, Daniele Ferrari, Denise Pires Marafon, Fulvio Parentin, Cinzia de Libero, Serena Pastore, Silvana Guerriero, Maria Elisabetta Zannin, Giovanni Filocamo, Vanessa Cecchin, Valentina Muratore, Fernanda Falcini |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
Male
medicine.medical_specialty Adolescent Immunology Arthritis Anti-TNF Agents Juvenile idiopathic arthritis Treatment Uveitis Rheumatology Immunology and Allergy 03 medical and health sciences 0302 clinical medicine Refractory Internal medicine medicine Adalimumab Humans In patient Anti-TNF agents Child Adverse effect 030203 arthritis & rheumatology business.industry medicine.disease Arthritis Juvenile Infliximab Safety profile Treatment Outcome Antirheumatic Agents Child Preschool 030221 ophthalmology & optometry Female business Immunosuppressive Agents medicine.drug |
| Popis: | Objective.Anti-TNF-α agents have significantly changed the management of juvenile idiopathic arthritis (JIA). We evaluated the safety and efficacy of adalimumab (ADA) and infliximab (IFX) for the treatment of JIA-associated uveitis in patients treated for ≥ 2 years.Methods.Patients with JIA-associated uveitis treated with IFX and ADA were managed by a standardized protocol and data were entered in the ORCHIDEA registry. At baseline, all patients were refractory to standard immunosuppressive treatment or were corticosteroid-dependent. Data recorded every 3 months were uveitis course, number/type of ocular flares and complications, drug-related adverse events (AE), and treatment switch or withdrawal. Data of patients treated for ≥ 2 years were analyzed by descriptive statistics.Results.Up to December 2014, 154 patients with ≥ 24 months followup were included in the study. Fifty-nine patients were treated with IFX and 95 with ADA. Clinical remission, defined as the absence of flares for > 6 months on treatment, was achieved in 69 patients (44.8%), with a better remission rate for ADA (60.0%) as compared to IFX (20.3%; p < 0.001). A significant reduction of flares was observed in all patients without difference between the 2 treatment modalities. The number of new ocular complications decreased in both groups but was lower for ADA (p = 0.015). No serious AE were recorded; 16.4% of patients experienced 35 minor AE and the incidence rate was lower with ADA than with IFX.Conclusion.At the 2-year followup, ADA showed a better efficacy and safety profile than IFX for the treatment of refractory JIA-associated uveitis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|